Arnhem, the Netherlands – Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") is pleased to announce that its new generation Rapamycin Target Eluting Coronary Stent System Firehawk Liberty™ has received CE Mark on March 22, 2019.
The revolutionary third-generation drug eluting stent Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") is a result of eight-year R&D of MicroPort®, and it is a drug-eluting stent featuring strut in-groove coating and precision target drug-releasing patent technology. Firehawk® adopts unique abluminal laser-cut groove coating design and target-eluting technology, and combines the merits of bare metal stent and drug eluting stent, which allows Firehawk® to achieve the same clinical efficacy with significantly lower drug loading. In September 2018, the results of the Firehawk® TARGET AC European trial were published on the website of the world leading medical journal the Lancet. This is the first time that clinical data from a China manufactured drug eluting stent has been published in the Lancet since its first publication nearly 200 years ago.
The new generation Rapamycin Target Eluting Coronary Stent System Firehawk Liberty™ introduces an improvement for its delivery system. It continues to feature the target drug eluting and adopts an innovative balloon technique to improve its dilation performance, which can further elevate the crossability, trackability and pushability of the product to make the stent more crossable with better vessel wall apposition after deployment.
Prior to Firehawk Liberty™, Firehawk® was granted the CE Mark in 2015. The approval for Firehawk Liberty™ in the European Union is set to help MicroPort® provide the physicians with more options in the field of PCI treatment. MicroPort® will continue to be committed to introducing more high-quality, innovative and high-end medical device products to the overseas markets, so as to provide patients with more comprehensive therapeutic solutions.